相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Walking impairs cognitive performance among people with multiple sclerosis but not controls
Matthew B. Downer et al.
HUMAN MOVEMENT SCIENCE (2016)
ULTRASOUND DETECTION OF KNEE JOINT DEGENERATION IN PATIENTS WITH MULTIPLE SCLEROSIS
Selma Eroglu et al.
JOURNAL OF REHABILITATION MEDICINE (2016)
Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern
Bjoern Zoerner et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern
Bjoern Zoerner et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Distribution-based estimates of minimum clinically important difference in cognition, arm function and lower body function after slow release-fampridine treatment of patients with multiple sclerosis
H. B. Jensen et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Clinical response and tolerability of fampridine in clinical practice
Eva Costa-Arpin et al.
NEURODEGENERATIVE DISEASE MANAGEMENT (2016)
Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine)
Philipp M. Keune et al.
BMC NEUROLOGY (2015)
Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients
Katja Pavsic et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2015)
Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial
Angela Applebee et al.
CLINICAL THERAPEUTICS (2015)
Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life
Etienne Allart et al.
JOURNAL OF NEUROLOGY (2015)
Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders
A. C. Lo et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2015)
Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials
Andrew D. Goodman et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis
Daniel Kantor et al.
POSTGRADUATE MEDICINE (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
Larissa Shamseer et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
Larissa Shamseer et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials
Andrew D. Goodman et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Long-term effects of dalfampridine in patients with multiple sclerosis
T. Ruck et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2014)
Within-day variability on short and long walking tests in persons with multiple sclerosis
Peter Feys et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2014)
Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study
Michelle H. Cameron et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Changes in cognition, arm function and lower body function after Slow-Release Fampridine treatment
H. B. Jensen et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Defining the clinical course of multiple sclerosis The 2013 revisions
Fred D. Lublin et al.
NEUROLOGY (2014)
Walking while talking in patients with multiple sclerosis: The impact of specific cognitive loads
G. Allai et al.
NEUROPHYSIOLOGIE CLINIQUE-CLINICAL NEUROPHYSIOLOGY (2014)
Timed 25-Foot Walk Direct evidence that improving 20% or greater is clinically meaningful in MS
Jeremy Hobart et al.
NEUROLOGY (2013)
Enhancing Neural Transmission in Multiple Sclerosis (4-Aminopyridine Therapy)
Andrew D. Goodman et al.
NEUROTHERAPEUTICS (2013)
Sustained-Release Fampridine (4-Aminopyridine) in Multiple Sclerosis: Efficacy and Impact on Motor Function
Meheroz H. Rabadi et al.
DRUGS IN R&D (2013)
Social and economic burden of walking and mobility problems in multiple sclerosis
James Pike et al.
BMC NEUROLOGY (2012)
Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis
Craig I. Coleman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
The impact of slower walking speed on activities of daily living in patients with multiple sclerosis
M. Yildiz
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2012)
Gait Speed and Survival in Older Adults
Stephanie Studenski et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Impact of Walking Impairment in Multiple Sclerosis Perspectives of Patients and Care Partners
Nicholas G. LaRocca
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2011)
A Phase 3 Trial of Extended Release Oral Dalfampridine in Multiple Sclerosis
Andrew D. Goodman et al.
ANNALS OF NEUROLOGY (2010)
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial
Andrew D. Goodman et al.
LANCET (2009)
Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls
Myla D. Goldman et al.
MULTIPLE SCLEROSIS JOURNAL (2008)
Dose comparison trial of sustained-release fampridine in multiple sclerosis
A. D. Goodman et al.
NEUROLOGY (2008)
Walking capacities in multiple sclerosis measured by global positioning system odometer
A. Creange et al.
MULTIPLE SCLEROSIS (2007)
Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis
J. J. Kragt et al.
MULTIPLE SCLEROSIS JOURNAL (2006)
Six-minute walk distance as a measure of functional exercise capacity in multiple sclerosis
S Savci et al.
DISABILITY AND REHABILITATION (2005)
The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite
ELJ Hoogervorst et al.
MULTIPLE SCLEROSIS (2004)
Measuring the impact of MS on walking ability - The 12-Item MS Walking Scale (MSWS-12)
JC Hobart et al.
NEUROLOGY (2003)
Quantitative functional measures in MS: What is a reliable change?
SR Schwid et al.
NEUROLOGY (2002)
分享论文
